Navigation Links
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
Date:7/10/2009

PARSIPPANY, N.J. and INDIANAPOLIS, July 10 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Effient(TM) (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). PCI usually includes the placement of a stent to help keep the artery open.

Effient (pronounced Ef-fee-ent) helps keep blood platelets from sticking together to form clots, which can block an artery. Taking Effient with aspirin after PCI has been shown to reduce the chances of having a cardiac event (such as a heart attack) and stent-related blood clots (known as stent thrombosis) among patients with acute coronary syndromes (ACS), a common cardiovascular condition.

"After more than a decade of research and testing, we are proud to provide this new treatment option to patients with ACS who are managed with PCI," said Takashi Shoda, president and chief executive officer, Daiichi Sankyo Company, Limited. "Our Daiichi Sankyo and Lilly alliance will launch Effient in the U.S. in the coming weeks."

"The FDA approval of Effient is a major step forward in the treatment of acute coronary syndromes," said John Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company. "The Daiichi Sankyo/Lilly alliance has provided doctors with an important new option that provides greater protection against thrombotic cardiovascular events to help those suffering with ACS who are being managed with PCI."

Effient should be initiated with a loading dose of 60 mg followed by a maintenance dose of 10 mg once daily. In addition, for those
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Daiichi Sankyo, Inc. Celebrates the Growth of Its U.S. Headquarters
2. Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
3. Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
4. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
5. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
6. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
7. Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize
8. Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
9. Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
10. Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
11. Lilly Declares Third-Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
(Date:4/23/2014)... the depletion of self-control, according to research published in ... for Psychological Science. , Self-control can be difficult ... on a boring textbook are hard things to do. ... Exerting self-control for a long period seems to "deplete" ... , "It is as if self-control is a limited ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... - Over the last few decades researchers have characterized ... of physiology and behavior in all types of species, ... have been identified, but researchers surmise there are more. ... the University of Pennsylvania wondered if big-data approaches could ... investigators, led by John Hogenesch, PhD, professor of Pharmacology ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... study says, , MONDAY, Nov. 9 (HealthDay News) -- Researchers ... penises by growing new penile tissue in the lab and ... application is a ways off, researchers say the technique could ... men. , "We were able to show the tissue was ...
... ... 2010, Provides First Responders with a Forensic Toolkit , ... Cambridge, MA (Vocus) November 9, 2009 -- When Stefan Schmitt of ... Afghanistan , he realized he would need a team of experts to help interpret the ...
... Ambassador , WHITE PLAINS, N.Y., Nov. 9 Joshua ... many underdeveloped organs that doctors could not say whether he would ... hear. Today, the 6-year-old was named March of Dimes 2010 National ... of motherhood and I was completely devastated. My husband, Lee, and ...
... however , MONDAY, Nov. 9 (HealthDay News) -- After a ... of cancer recurrence in the affected breast, a new study ... increased risk of developing breast cancer, and experts have suspected ... increased risk of cancer recurrence at the site of the ...
... PITTSFIELD, Maine, Nov. 9 At a time when ... concerned about finding affordable health insurance, they now have ... Options® Preferred Provider Organization (PPO) Medicare Advantage plan provides ... a Medicare Supplement plan. People with Medicare can ...
... , Neurologists will use funds to move lab ... pain from nerve damage , ANN ARBOR, Mich., ... of Neurology have received a $1.8 million grant to ... condition in which patients experience pain because of damage ...
Cached Medicine News:Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , ... 2020; significant funding gaps remain, others must join effort , ... and Melinda Gates announced today that their foundation will commit ... research, develop and deliver vaccines for the world,s poorest countries. ...
... , UNION CITY, Calif. , Jan. 28 ... point-of-care blood analysis systems, today reported financial results for the fiscal quarter ... , Revenues of $31.0 million , up 15% over last ... million , up 9% over last year,s comparable quarter. Veterinary market ...
Cached Medicine Technology:Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 2Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 3Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 4Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 5Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 6Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 2Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 3Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 4Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 5Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 6Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 7Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 8Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 9Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 10Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 11Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 12
... A concentrated enzymatic ... and semi-automated hematology instruments. ... on all Abbott CELL-DYN® ... differential instruments. The shelf ...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
Medicine Products: